Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00747747
Other study ID # GAL-01-2007
Secondary ID EudraCT: 2007-00
Status Completed
Phase Phase 4
First received September 4, 2008
Last updated March 12, 2012
Start date November 2007
Est. completion date February 2010

Study information

Verified date March 2012
Source Galsor S.r.l.
Contact n/a
Is FDA regulated No
Health authority Italy: The Italian Medicines Agency
Study type Interventional

Clinical Trial Summary

The goal of the study is to demonstrate that SINUclean DM® spray, added to the standard (amoxicillin/clavulanate) therapy of the acute episode of sinusitis (acute, subacute or chronic), is safe ad capable to determine the resolution of the symptoms in a shorter time in comparison with the standard therapy without co-adjuvant, or with simple saline lavage.


Description:

The randomized subject with diagnosis of acute episode of sinusitis with symptoms and mucus in the paranasal sinuses, will treat his/her condition with background amoxicillin/clavulanate and with inhalation of Sinuclean or Saline, while the control group will not use any spray for symptom relief. Anti-histaminic, steroidal anti-inflammatory drugs are forbidden. The patient is requested to evaluate his state of symptoms by recording in a diary

- the pain or feeling of facial oppression;

- nasal dripping anterior or posterior;

- nasal congestion. SCALE 0 = no symptom

1. = mild symptom: clearly perceptible, but easily tolerated

2. = moderate symptom: clear awareness of the symptom, that is annoying but tolerable

3. = severe: symptom very annoying, difficult to tolerate, interfering with the ordinary life Four measures per day (2 for administration of the therapy - before/after) of which the median will be used; plus an evening measure "retrospective" of the past 12 hours.

If possible it will be assessed the status of paranasal sinuses before and after the treatment with a CT scan.

The treatment intervals is the week. After baseline and start of treatment, are planned two control visit. The subject will complete the study at the first control visit without symptoms. After the second visit, if the symptoms are still present, the subject will complete as a "treatment-failure".


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date February 2010
Est. primary completion date January 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female sex.

- Age > 18 years old.

- Diagnosis of acute episode of sinusitis (in an acute, subacute or chronic background), confirmed with a CT scan image.

- Presence of mucus in para-nasal sinuses.

- Symptoms of facial pain associated to the congestion of the mucosa of the paranasal sinuses for at least three days.

- Written informed consent.

- Expressed intention of compliance with the study requirements.

Exclusion Criteria:

- In case of female subject: ongoing pregnancy or lactating; or condition of fecundity without abstinence.

- Assumption, during the study, of drugs that can interfere with the evaluation of the investigational drug (see Section "Concomitant Therapy")

- Possible necessity of treatment, during the study, with drugs that are not allowed (see section "Concomitant Therapy").

- Clinical conditions (systemic pathologies or other) that can interfere with the assessment of the safety and efficacy of the investigational drug, in example: viral or allergic rhinitis with active secretive symptomatology, presence of visible nasal polyps, diagnosis of immobile cilia syndrome, diseases determining immunodeficiency cystic fibrosis immunocompromission renal insufficiency, dialysis, pathology of other apparatus that, in the opinion of the investigator, necessity of a supplementary antibiotic therapy,due to other pathologies, besides the one standard of the sinusitis.

- Psychical conditions not compatible with the participation to the clinical trial.

- Alcohol abuse or other dependencies on stupefacents

- Smoking during the period of the study

- History of intolerance or allergy to the components of SINUclean DMĀ®

- Surgical or medical intervention that can jeopardize the complete performance of the trial, in the 4 wks preceding the administration of the informed consent

- Planning of a surgical or medical intervention that can jeopardize the completion of the trial

- Participation to other clinical trials, ongoing or terminated since less than 30 days before the beginning of the present experiment.

- Preceding randomization in this trial.

- Be component of the investigators' staff or be a relative of a member of the staff.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Saline solution
3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
Device:
Sinuclean DM Spray
3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed

Locations

Country Name City State
Italy University Cattolica del Sacro Cuore Rome Lazio

Sponsors (1)

Lead Sponsor Collaborator
Galsor S.r.l.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Presence of Mucus in the Paranasal Sinuses (Outcome Measure Percentage of Patients) Mucus detection in paranasal sinuses by clinical assessment(Outcome measure Percentage of patients) After one week No
Primary Presence of Mucus in the Paranasal Sinuses (Outcome Measure Percentage of Patients) Mucus detection in paranasal sinuses by clinical assessment(Outcome Measure Percentage of patients) After two weeks Yes
Secondary FACIAL PAIN Daily Retrospective Ranking of Symptoms as Assessed by the Subject Patient's daily diary retrospective ranked assessment of symptoms (0,1,2,3 with 0 = no symptoms; frequencies of patients with rank "0" were compared as outcome measure between groups After one week No
Secondary FACIAL PAIN Daily Retrospective Ranking of Symptoms as Assessed by the Subject Patient's daily diary retrospective ranked assessment of symptoms (0,1,2,3 with 0 = no symptoms; frequencies of patients with rank "0" were compared as outcome measure between groups. After two weeks No
Secondary Recovery of Sinusitis Per Clinical Assessment(Outcome Measure Percentage of Patients) Clinical assessment of healing of the sinusitis episode(Outcome Measure Percentage of patients healed). Healing was assessed clinically by the physician as recovery of the condition prior to the diagnosis of the episode of sinusitis, without need of medical treatment. After one week No
Secondary Recovery of Sinusitis Per Clinical Assessment (Outcome Measure Percentage of Patients) Clinical assessment of healing of the sinusitis episode (Outcome Measure Percentage of patients healed. Healing was assessed clinically by the physician as recovery of the condition prior to the diagnosis of the episode of sinusitis, without need of medical treatment. After two weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT03584178 - The Long-Term Safety of Budesonide for Patients With Chronic Rhinosinusitis N/A
Completed NCT06016335 - MRI-based Synthetic CT Images of the Head and Neck N/A
Active, not recruiting NCT02278484 - Sinus Balloon Dilation in Pediatric Patients N/A
Withdrawn NCT02071667 - Association of Periostin Levels and Chronic Sinusitis N/A
Completed NCT01420471 - Medicated Punctured-Glove-Finger Spacer Study Phase 4
Completed NCT01118312 - Study of Asthma and Nasal Steroids Phase 4
Completed NCT00645762 - Balloon REmodeling Antrostomy THErapy Study Phase 2
Completed NCT01685229 - Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis
Active, not recruiting NCT03943121 - The Effects of Steroid-eluting Stent Implant for the Treatment of Eosinophilic Chronic Rhinosinusitis With Nasal Polyps N/A
Withdrawn NCT02900794 - Gold Laser Vs. Micro-Debriders for Functional Endoscopic Sinus Surgery N/A
Terminated NCT02630472 - Topical Irrigation Therapy for CRS Phase 1/Phase 2
Completed NCT01442740 - 15-Degree Tilt, Head Up, Feet Down Body Position for Sinus Surgery Patients N/A
Completed NCT01001039 - Validation of the Facial and Cephalic Pain Inventory N/A
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Completed NCT00335309 - Maxillary Sinus Irrigation in the Management of Chronic Rhinosinusitis N/A
Completed NCT00242437 - Hemostatic Matrix in Endoscopic Sinus Surgery Phase 4
Completed NCT00236522 - A Comparison of the Safety and Efficacy of Two Different Regimens of Levofloxacin in the Treatment of Acute Bacterial Sinusitis(Sinus Infection) in Adults. Phase 3
Completed NCT01717274 - Hot Saline Irrigation Study N/A
Completed NCT01166945 - Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children N/A
Not yet recruiting NCT00545961 - Middle Meatal Bacteriology During Acute Respiratory Infection in Children Phase 4

External Links